Effects of highly active antiretroviral therapy on vaccine-induced humoral immunity in HIV-infected adults

HIV Medicine

Volumn 11, Issue 8, 2010, Pages 535-539

  Gonzalez R ^a   Castro, P ^a   Garcia F ^a   Plana, M ^a   Bayas, J M ^a   Lafuente, S ^a   Serrano, B ^a   Mora, B ^a   Argelich, R ^a   Gatell, J M ^a   Vilella, A ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Highly active antiretroviral therapy; HIV; Humoral immunity

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G ANTIBODY; PLACEBO;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VACCINATION; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIBODIES, VIRAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PLACEBOS; VACCINATION; VIRAL LOAD; VIRAL VACCINES;

EID: 77955251964     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2010.00830.x     Document Type: Article

References (16)

1. Ada G. The immunology of vaccination. Vaccines 2004, 31-45. Plotkin SAOrenstein WA. In, eds, 4th ed, Philadelphia: Saunders
2. Esser MT, Marchese RD, Kierstead LS. Memory T cells and vaccines. Vaccine 2003, 21:419-430.
3. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007, 357:1903-1915.
4. Recommended adult immunization schedule - United States, 2009. Morbid Mortal Wkly Rep 2008, 57. Centers for Disease Control and Prevention.
5. Janoff EN, Hardy WD, Smith PD, Wahl SM. Humoral recall responses in HIV infection. Levels, specificity and affinity of antigen-specific IgG. J Immunol 1991, 147:2130-2135.
6. Ballet JJ, Couderc LJ, Rabian-Herzog C. Impaired T-lymphocyte-dependent immune responses to microbial antigens in patients with HIV-1-associated persistent generalized lymphadenopathy. AIDS 1988, 2:291-297.
7. Kroon FP, van Dissel JT, Labadie J, van Loon AM, van Furth R. Antibody response to diphtheria, tetanus, and poliomyelitis vaccines in relation to the number of CD4+ T lymphocytes in adults infected with human immunodeficiency virus. Clin Infect Dis 1995, 21:1197-1203.
8. Lange CG, Lederman NM, Medvik K. Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS 2003, 17:2015-2023.
9. Jacobson MA, Khayam-Bashi H, Martin JN, Black D, Ng V. Effect of long-term highly active antiretroviral therapy in restoring HIV-induced abnormal B-lymphocyte function. J Acquir Immune Defic Syndr 2002, 31:472-477.
10. Castro P, Plana M, González R. Influence of a vaccination schedule on viral load rebound and immune responses in successfully treated HIV-infected patients. AIDS Res Hum Retroviruses 2009, 25((12)):1249-1259.
11. Siber GR, Priehs C, Madore DV. Standardization of antibody assays for measuring the response to pneumococcal infection and immunization. Pediatr Infect Dis J 1989, 8((1 Suppl)):S84-S91.
12. Dieye TN, Sow PS, Simonart T. Immunologic and virologic response after tetanus toxoid booster among HIV-1 and HIV-2-infected Senegalese individuals. Vaccine 2002, 20:905-913.
13. Hess G, Clemens R, Bienzle U, Schönfeld C, Schunck B, Bock HL. Immunogenicity and safety of an inactivated hepatitis A vaccine in anti-HIV positive and negative homosexual men. J Med Virol 1995, 46:40-42.
14. Amendola A, Tanzi E, Zappa A. Safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-1 infected former drug users. Vaccine 2002, 20:3720-3724.
15. Moir S, Malaspina A, Ho J. Normalization of B cell counts and subpopulations after antiretroviral therapy in chronic HIV disease. J Infect Dis 2008, 197:572-579.
16. Titanji K, De Milito A, Cagigi A. Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood 2006, 108:1580-1587.